Literature DB >> 30530753

Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma.

Chia-Ching Wang1, Cassandra Thanh1, Erica A Gibson1, Maya Ball-Burack1, Louise E Hogan1, Benjamin Descours2, Norman Jones1, Alexander B Carvidi1, Sadie Munter1, Sonia Bakkour3, Michael P Busch3, Jeffrey M Milush1, Steven G Deeks1, Timothy J Henrich1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30530753      PMCID： PMC6290106          DOI： 10.1182/bloodadvances.2018024364

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  16 in total

1.  CD30 induction of human immunodeficiency virus gene transcription is mediated by TRAF2.

Authors:  E N Tsitsikov; D A Wright; R S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

Review 2.  Markers of the HIV-1 reservoir: facts and controversies.

Authors:  Timothée Bruel; Olivier Schwartz
Journal:  Curr Opin HIV AIDS       Date:  2018-09       Impact factor: 4.283

3.  Significant link between sCD30 changes and HIV viremia in patients treated with HAART.

Authors:  Priscilla Biswas; Alessandro Cozzi-Lepri; Fanny Delfanti; Andrea Galli; Vincenzo Colangeli; Maria Cristina Moioli; Antonella Scarchilli; Nicola Abrescia; Gianmarco Vigevani; Antonella D'Arminio-Monforte; Roberto Novati; Adriano Lazzarin
Journal:  J Med Virol       Date:  2006-12       Impact factor: 2.327

Review 4.  Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.

Authors:  Youry Kim; Jenny L Anderson; Sharon R Lewin
Journal:  Cell Host Microbe       Date:  2018-01-10       Impact factor: 21.023

Review 5.  CD30 in normal and neoplastic cells.

Authors:  R Chiarle; A Podda; G Prolla; J Gong; G J Thorbecke; G Inghirami
Journal:  Clin Immunol       Date:  1999-02       Impact factor: 3.969

6.  Evaluation of the Aptima HIV-1 Quant Dx Assay for HIV-1 RNA Quantitation in Different Biological Specimen Types.

Authors:  Christina Yek; Marta Massanella; Tashi Peling; Kristen Lednovich; Sangeetha V Nair; Andrew Worlock; Milenka Vargas; Sara Gianella; Ronald J Ellis; Matthew C Strain; Michael P Busch; C Thomas Nugent; Douglas D Richman
Journal:  J Clin Microbiol       Date:  2017-06-07       Impact factor: 5.948

7.  High serum level of soluble CD30 in acute primary HIV-1 infection.

Authors:  G Pizzolo; F Vinante; G Nadali; M Krampera; L Morosato; M Chilosi; R Raiteri; A Sinicco
Journal:  Clin Exp Immunol       Date:  1997-05       Impact factor: 4.330

8.  High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS.

Authors:  G Pizzolo; F Vinante; L Morosato; G Nadali; M Chilosi; G Gandini; A Sinicco; R Raiteri; G Semenzato; H Stein
Journal:  AIDS       Date:  1994-06       Impact factor: 4.177

9.  CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF.

Authors:  C A Smith; H J Gruss; T Davis; D Anderson; T Farrah; E Baker; G R Sutherland; C I Brannan; N G Copeland; N A Jenkins
Journal:  Cell       Date:  1993-07-02       Impact factor: 41.582

10.  Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30.

Authors:  Louise E Hogan; Joshua Vasquez; Kristen S Hobbs; Emily Hanhauser; Brandon Aguilar-Rodriguez; Rajaa Hussien; Cassandra Thanh; Erica A Gibson; Alexander B Carvidi; Louis C B Smith; Shahzada Khan; Martin Trapecar; Shomyseh Sanjabi; Ma Somsouk; Cheryl A Stoddart; Daniel R Kuritzkes; Steven G Deeks; Timothy J Henrich
Journal:  PLoS Pathog       Date:  2018-02-22       Impact factor: 6.823
View more
  6 in total

1.  Circulating CD30+CD4+ T Cells Increase Before Human Immunodeficiency Virus Rebound After Analytical Antiretroviral Treatment Interruption.

Authors:  Cecilia A Prator; Cassandra Thanh; Shreya Kumar; Tony Pan; Michael J Peluso; Ronald Bosch; Norman Jones; Jeffrey M Milush; Sonia Bakkour; Mars Stone; Michael P Busch; Steven G Deeks; Peter W Hunt; Timothy J Henrich
Journal:  J Infect Dis       Date:  2020-03-16       Impact factor: 5.226

Review 2.  The Potential of Long-Acting, Tissue-Targeted Synthetic Nanotherapy for Delivery of Antiviral Therapy Against HIV Infection.

Authors:  Anna Halling Folkmar Andersen; Martin Tolstrup
Journal:  Viruses       Date:  2020-04-07       Impact factor: 5.048

Review 3.  The Quest for Cellular Markers of HIV Reservoirs: Any Color You Like.

Authors:  Gilles Darcis; Ben Berkhout; Alexander O Pasternak
Journal:  Front Immunol       Date:  2019-09-20       Impact factor: 7.561

Review 4.  Immunotherapy in People With HIV and Cancer.

Authors:  Camille E Puronen; Emily S Ford; Thomas S Uldrick
Journal:  Front Immunol       Date:  2019-08-28       Impact factor: 7.561

5.  Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1.

Authors:  Michael J Peluso; Cassandra Thanh; Cecilia A Prator; Louise E Hogan; Victor M Arechiga; Sophie Stephenson; Philip J Norris; Clara Di Germanio; Dietmar Fuchs; Henrik Zetterberg; Steven G Deeks; Magnus Gisslén; Richard W Price; Timothy J Henrich
Journal:  J Virus Erad       Date:  2020-02-20

6.  Replicate Aptima Assay for Quantifying Residual Plasma Viremia in Individuals on Antiretroviral Therapy.

Authors:  Sonia Bakkour; Xutao Deng; Peter Bacchetti; Eduard Grebe; Leilani Montalvo; Andrew Worlock; Mars Stone; Steven G Deeks; Douglas D Richman; Michael P Busch
Journal:  J Clin Microbiol       Date:  2020-11-18       Impact factor: 5.948
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.